Current and future antifungal therapy: New targets for antifungal agents

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 2, 1999, Pages 151-162

  Andriole, Vincent T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCD; ALLYLAMINE DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BENANOMICIN A; CLOTRIMAZOLE; CORTICOSTEROID; DOLASTATIN 10; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; L AMB; N DIMETHYLMINOACETYL PARTRICIN A 2 DIMETHYLAMINOETHYLAMIDE DIASCORBIC ACID; NIKKOMYCIN; NUCLEOSIDE ANALOG; NYSTATIN; PNEUMOCANDIN DERIVATIVE; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PRADIMICIN A; PYRROLE DERIVATIVE; SORDARIN; TERBINAFINE; THIOCARBAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLUS; BONE MARROW TOXICITY; CANDIDA; CLINICAL TRIAL; CRYPTOCOCCUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INFUSION; DRUG POTENCY; ENDOCRINE DISEASE; FUSARIUM; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; TOPICAL DRUG ADMINISTRATION; CHEMISTRY; CLASSIFICATION; MICROBIOLOGY; OPPORTUNISTIC INFECTION; RESEARCH;

ANTIFUNGAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; OPPORTUNISTIC INFECTIONS; RESEARCH;

EID: 0033170406     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.2.151     Document Type: Review

References (106)

1. Andriole, V. T. (1998). Current and future therapy of invasive fungal infections. In Current Clinical Topics in Infectious Diseases, Vol. 18 (Remington, J. & Swartz, M., Eds), pp. 19-36. Blackwell Sciences, Malden, MA.
2. Groll, A. H., Piscitelli, S. C. & Walsh, T. J. (1998). Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Advances in Pharmacology 44, 343-500.
3. Anaissie, E. J. (1992). Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clinical Infectious Diseases 14, Suppl. 1, 43-53.
4. Pfaller, M. A. & Wenzel, R. (1992). The impact of changing epidemiology of fungal infections in the 1990s. European Journal of Microbiology and Infectious Diseases 11, 287-91.
5. Richardson, M. D. (1991). Opportunistic and pathogenic fungi. Journal of Antimicrobial Chemotherapy 28, Suppl. A, 1-11.
6. Walsh, T. J. (1992). Invasive fungal infections: problems and challenges in developing new antifungal compounds. In Emerging Targets in Antibacterial and Antifungal Chemotherapy (Sutcliffe, J. & Georgopapadakou, N. H. Eds), pp. 349-73. Chapman & Hall, New York.
7. Georgopapadakou, N. H. & Walsh, T. J. (1996). Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrobial Agents and Chemotherapy 40, 270-91.
8. Beck-Sague, C. M. & Jarvis, W. R. (1993). Secular trends in the epidemiology of nosocomial fungal infections in the U.S. Journal of Infectious Diseases 167, 1247-51.
9. Denning, D. W. (1991). Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. Journal of Antimicrobial Chemotherapy 28, Suppl. B, 1-6.
10. Diamond, R. D. (1991). The growing problem of mycoses in patients infected with the human immunodeficiency virus. Reviews of Infectious Diseases 13, 480-6.
11. Vazquez, J. A., Sanchez, V., Dmuchowski, C., Dembry, L. M., Sobel, J. D. & Zervos, M. J. (1993). Nosocomial acquisition of Candida albicans: an epidemiologic study. Journal of Infectious Diseases 168, 195-201.
12. Bodey, G. P. (1993). Antifungal agents. In Candidosis: Pathogenesis, Diagnosis and Treatment (Bodey, G. P., Ed.), pp. 371-406. Raven Press, New York.
13. Andriole, V. T. & Bodey, G. P. (Eds) (1994). Pocket Guide to Systemic Antifungal Therapy. Scientific Therapeutics, Springfield, NJ.
14. Current, W. L., Tang, J., Boylan, C., Watson, P., Zeckner, W., Turner, W. et al. (1995). Glucan biosynthesis as a target for antifungal: the echinocandin class of antifungal agents. In Antifungal Agents: Discovery and Mode (Dixon, G. K., Copping, L. G. & Hollomon, D. W., Eds), pp. 143-160. BIOS, Oxford.
15. Bolard, J. (1986). How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochemica et Biophysica Acta 864, 257-304.
16. Warnock, D. W. (1991). Amphotericin B: an introduction. Journal of Antimicrobial Chemotherapy 28, Suppl. B, 27-38.
17. Hazen, E. & Brown, R. (1950) Two antifungal agents produced by a soil actinomycete. Science 112, 423.
18. Hazen, E. & Brown, R. (1951). Fungicidin, an antibiotic produced by a soil actinomycete. Proceedings of the Society of Experimental Biology 76, 93.
19. Bennett, J. E. (1992). Developing drugs for the deep mycoses: A short history. In New Strategies in Fungal Disease (Bennett, J. E., Hay, R. J. & Peterson, P. K., Eds), pp. 3-12. Churchill Livingstone, London.
20. Gold, W. (1995). Amphotericins A and B: antifungal antibiotic produced by streptomycete. I. In vitro studies. Antibiotic Annals, 579-86.
21. Andriole, V. T. & Kravetz, H. M. (1962). The use of amphotericin B in man. Journal of the American Medical Association 180, 269-72.
22. Kravetz, H. M., Andriole, V. T., Huber, M. A. & Utz, J. P. (1961). Oral administration of solubilized amphotericin B. New England Journal of Medicine 265, 183-4.
23. Gallis, H. A., Drew, R. H. & Pickard, W. W. (1990). Amphotericin B: 30 years of clinical experience. Reviews of Infectious Diseases 12, 308-29.
24. Bodey, G. P. (1996). Antifungal agents. In Current ID Drugs (Andriole, V. T., Ed.), pp. 229-48. Current Medicine, Philadelphia, PA.
25. Gallis, H. A. (1996). Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Clinical Infectious Diseases 22, Suppl. 2, S145-7.
26. Hiemenz, J. W. & Walsh, T. J. (1996). Lipid formulations of amphotericin B: recent progress and future directions. Clinical Infectious Diseases 22, Suppl. 2, S133-44.
27. Lopez-Berestein, G., Bode, G. P., Fainstein, V., Keating, M., Frankel, L. S., Zeluff, B. et al. (1989). Treatment of systemic fungal infections with liposomal amphotericin B. Archives of Internal Medicine 149, 2533-6.
28. Kline, S., Larsen, T. A., Fieber, L, Fishbach, R., Greenwood, M., Harris, R. et al. (1995). Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clinical Infectious Diseases 21, 1154-8.
29. Janknegt, R., Van Etten, E. W. M. & de Marie, S. (1996). Lipid formulations of amphotericin B. Current Opinion in Infectious Diseases 9, 403-6.
30. Oppenheim, B. A., Herbrecht, R. & Kusne, S. (1995). The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clinical Infectious Diseases 21, 1145-53.
31. Bowden, R. A., Cays, M., Gooley, T., Mamelok, R. D. & van Burik, J. (1996). Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. Journal of Infectious Diseases 173, 1208-15.
32. Sharkey, P. K., Graybill, J. R., Johnson, E. S., Hausrat, S. G., Pollard, R. B., Kolokathis, A. et al. (1996). Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases 22, 315-21.
33. White, M. H., Bowden, R. A., Sandler, E. S., Graham, M. L., Noskin, G. A., Wingard, J. R. et al. (1998). Randomized, doubleblind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clinical Infectious Diseases 27, 296-302.
34. Wingard, J. E. (1997). Conventional versus lipid formulations of amphotericin B. In Focus on Fungal Infections VII (Anaissie, E. J. & Rinaldi, M. G., Chairmen), p. 33. San Antonio, Texas, March 12-14. Imedex Inc., Alpharetta, GA.
35. Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwich, G., Lee, L. et al. (1998). Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clinical Infectious Diseases 26, 1383-96.
36. Joly, V., Aubry, P., Ndayiragide, A., Carriere, I., Kawa, E., Mlika-Cabanne, N. et al. (1996). Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or intra-lipid for the treatment of AIDS-associated cryptococcal meningitis. Clinical Infectious Diseases 23, 556-62.
37. Wallace, T. L., Paetznick, V., Cossum, P. A., Anaissie, E. (1998). Nyotran (liposomal nystatin) activity against disseminated Aspergillus fumigatus in neutropenic mice. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract B53, p. 9. American Society for Microbiology, Washington, DC.
38. Gonzalez, C. E., Giri, N., Shetty, D., Kligys, K., Love, W., Sein, T. et al. (1998). Efficacy of a lipid formulation of nystatin against invasive pulmonary aspergillosis. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract B54, p. 31. American Society for Microbiology, Washington, DC.
39. Rimaroli, C. & Bruzzese, T. (1998). In vitro activity of a new polyene, SPA-S-843, against yeasts. Antimicrobial Agents and Chemotherapy 42, 3012-3.
40. Grunberg, E., Titsworth, E. & Bennett, M. (1963). Chemotherapeutic activity of 5-fluorocytosine. Antimicrobial Agents and Chemotherapy 161, 556-8.
41. Sonne, L. J. (1978). Flucytosine to counter systemic mycoses. Drug Therapy 3, 55-63.
42. Plempel, M., Bartmann, K., Buchel, K. H. & Regel, E. (1969). First clinical experience in systemic mycoses with a new oral broad spectrum antimycotic. Deutsche Medizinische Wochenschrift 94, 1356.
43. Rex,. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., vander Horst, C. M. Edwards, J. G. et al. (1994). A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. New England Journal of Medicine 331, 1325-30.
44. Anaissie, E. J., Darouiche, R. O., Abi-Said, D., Uzun, O., Mera, J., Gentry, L. O. et al. (1996). Management of invasive candidal infections: results of a prospective randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clinical Infectious Diseases 23, 964-72.
45. Kauffman, C. A. (1996). Role of azoles in antifungal therapy. Clinical Infectious Diseases 22, Suppl. 2, 148-53.
46. Czwerwiec, F. S., Bilsker, M. S., Kamerman, M. L. & Bisno, A. L. (1993). Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis. American Journal of Medicine 94, 545-6.
47. Saag, M. S., Powderly, W. G., Cloud, G. A., Robinson, P., Grieco, M. H., Sharkey, P. K. et al. (1992). Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cyrptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. New England Journal of Medicine 326, 83-9.
48. van der Horst, C. M., Saag, M. S., Cloud, G. A., Hamill, R. J., Graybill, J. R., Sobel, J. O. et al. (1997). Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. New England Journal of Medicine 337, 15-21.
49. 3: demonstration of efficacy in a prospective, multicenter trial. Clinical Infectious Diseases 23, 1282-6.
50. Galgiani, J. N., Catanzasro, A. N., Cloud, G. A., Higgs, J., Friedman, B. A., Larsen, R. A. et al. (1993). Fluconazole therapy for coccidioidal meningitis. The NIAID Mycoses Study Group Annals of Internal Medicine 119, 28-35.
51. McKinsey, D. S., Kauffman, C. A., Pappas, P. G., Cloud, G. A., Girard, W. M. & Sharkey, P. K. (1996). Fluconazole therapy for histoplasmosis. Clinical Infectious Diseases 23, 996-1001.
52. Pappas, P. G., Bradsher, R. W., Chapman, S. W., Kauffman, C. A., Dine, A., Cloud, G. A. et al. (1995). Treatment of blastomycosis with fluconazole: A pilot study The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clinical Infectious Diseases 20, 267-71.
53. Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandraskar, P. H., Fox, B., Kaizer, H. et al. (1992). A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine 326, 845-51.
54. Schuman, P., Capps, L., Peng, G., Vazquez, J., Saur, W., Goldman, A. I. et al. (1997). Weekly fluconazole for the prevention of mucosal candidosis in women with HIV infection. A randomized double blind, placebo-controlled trial. Annals of Internal Medicine 126, 689-96.
55. Kauffman, C. A. (1994). Newer developments in therapy for endemic mycoses. Clinical Infectious Diseases 19, Suppl. 1, 28-32.
56. George, D., Miniter, P. & Andriole, V. T. (1996). Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrobial Agents and Chemotherapy 40, 86-91.
57. Troke, P. F., Brammer, K. W., Hitchcock, C. A., Yonren, S. & Sarantis, N. (1995). UK-109496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidosis models and early clinical efficacy in oro-pharyngeal candidosis (OPC). In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F73, p. 125. American Society of Microbiology, Washington, DC.
58. Perfect, J. R., Cox, G. M., Dodge, R. K. & Schell, W. A. (1996). In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy 40, 1910-3.
59. Schock, K., Marino, S., Baumgartner, T. & Andriole, V. T. (1998). Efficacy of a new triazole, BMS-207147, in a model of invasive aspergillosis in immunosuppressed, neutropenic rabbits. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J54, p. 466. American Society for Microbiology, Washington, DC.
60. Fung-Tomc, J. C., Huczko, E., Minassian, B. & Bonner, D. P. (1998). In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrobial Agents and Chemotherapy 42, 313-8.
61. Hata, K., Kimura, J., Miki, H., Toyosawa, T., Nakamura, T., Katsu, K. et al. (1996). In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrobial Agents and Chemotherapy 40, 2237-42.
62. Schell, W. A., De Almeida, G. M. D., Dodge, R. K., Okonogi, K. & Perfect, J. R. (1998). In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy 42, 2630-2.
63. Bartroli, J., Turmo, E., Alguero, M., Boncompte, E., Vericat, L. K., Garcia-Rafanell, J. et al. (1995). UR-9746 and UR-9751 : two new azole derivatives with potent oral antifungal activity. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F84, p. 127. American Society for Microbiology, Washington, DC.
64. Ramos, G., Cuenca-Estrella, M., Monzon, A., Martinez-Suarez, J. V. & Rodriguez-Tudela, J. L. (1998). In vitro comparative activity of UR-9825, fluconazole (FLZ) and itraconazole (ITR) against 254 yeast clinical isolates. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J10, p. 453. American Society for Microbiology, Washington, DC.
65. Yotsuki, A., Shimizu, K., Nishida, N., Hori, R., Ishii, N., Yamamoto, S. et al. (1995). T-8581, a new orally and parenterally active triazole antifungal in vitro and in vivo evaluation. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F82, p. 127. American Society for Microbiology, Washington, DC.
66. Fothergill, A. W., Salama, S. M. & Rinaldi, M. G. (1998). An in vitro head-to-head comparison of Syn2836, Syn2869, Syn2903, Sn2921, amphotericin B, fluconazole, and itraconazole against a spectrum of 90 clinically-significant fungi. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J117, p. 484. American Society for Microbiology, Washington, DC.
67. Yokoyama, K., Wang, I. & Miyaji, M. (1996). SSY726, a new triazole antifungal agent: in vitro and in vivo evaluation. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F75, p. 113. American Society for Microbiology, Washington, DC.
68. Petraitis, V., Petraitiene, R., Candelario, M., Fiel-Ridley, A., Groll, A., Sein, T. et al. (1998). Efficacy of LY303366, a semisynthetic echinocandin, against fluconazole-resistant esophageal candidosis. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J72, p. 471. American Society for Microbiology, Washington, DC.
69. Petraitiene, R., Petraitis, V., Groll, A., Candelario, M., Sein, T., Bell, A. et al. (1998). Efficacy of LY303366, a novel echinocandin, against disseminated candidosis in persistently neutropenic rabbits. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J73, p. 472. American Society for Microbiology, Washington, DC.
70. Abruzzo, G. K., Flattery, A. M., Gill, C. J., Kong, L., Smith, J. G., Krupa, D. et al. (1995). Evaluation of water-soluble pneumocandin analogs L-733560, L-705589 and L-731373 with mouse models of disseminated aspergillosis, candidosis and cryptococcosis. Antimicrobial Agents and Chemotherapy 39, 1077-81.
71. Smith, J. G., Abruzzo, G. K., Gill, C. J., Flattery, A. M., Kong, L., Rosen, H. et al. (1996). Evaluation of pneumocandin L-743872 in neutropenic mouse models of disseminated candidosis and aspergillosis. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F41, p. 107. American Society for Microbiology, Washington, DC.
72. Najvar, L., Graybill, J., Montalbo, E., Barchiesi, F. & Luther, M. (1996). Evaluation of L-743872 (872) in the treatment of murine histoplasmosis. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F43, p. 107. American Society for Microbiology, Washington, DC.
73. Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M. et al. (1997). In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743872). Antimicrobial Agents and Chemotherapy 41, 2326-32.
74. Abruzzo, G. K., Flattery, A. M., Gill, C. J., Kong, L, Smith, J. G., Pikounis, V. B. et al. (1997). Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidosis and cryptococcosis. Antimicrobial Agents and Chemotherapy 41, 2333-8.
75. Hajdu, R., Thompson, R., Sundelof, J. G., Pelak, B. A., Bouffard, F. A. & Dropinski, J. F. (1997). Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743872). Antimicrobial Agents and Chemotherapy 41, 2339-44.
76. Gonzalez, C. E., Groll, A. H., Giri, N., Shetty, D., Al-Mohsen, I, Sein, T. et al. (1998). Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrobial Agents and Chemotherapy 42, 2399-404.
77. Restrepo, M. I., Najvar, L. K., Fothergill, A. W. & Graybill, J. R. (1998). Pradimicin therapy of disseminated Candida tropicalis infection in the mouse. Medical Mycology 36, 181-4.
78. Li, R. K., Fothergill, A. W. & Rinaldi, M. G. (1996). In vitro antifungal activity of SP-920704 in combination with fluconazole and itraconazole. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F189, p. 132. American Society for Microbiology, Washington, DC.
79. Flores, M. E. & Hector, R. F. (1996). In vitro activity of the antifungal nikkomycin Z (SP-920704) in combination with fluconazole or itraconazole vs yeasts. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F190, p. 133. American Society for Microbiology, Washington, DC.
80. Graybill, J. R., Najvar, L. K., Bocanegra, R., Hector, R. F. & Luther, M. F. (1998). Efficacy of nikkomycin Z in the treatment of murine histoplasmosis. Antimicrobial Agents and Chemotherapy 42, 2371-4.
81. Milewski, S., Mignini, F., Micossi, L. & Borowski, E. (1998). Antihistoplasmal in vitro and in vivo effect of Lys-Nva-FMDP. Medical Mycology 36, 177-80.
82. Vaddi, K., Preston, C., Sugar, A. M., Aerts, J. M. F. G. & Friedman, B. (1998). Antifungal efficacy of recombinant human chitinase in murine candidosis and aspergillosis. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J53, p. 466. American Society for Microbiology, Washington, DC.
83. Ryder, N. S. & Leitner, I. (1996). Activity of terbinafine against Aspergillus in vitro, in combination with amphotericin B or triazoles. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract E54, p. 91. American Society for Microbiology, Washington, DC.
84. Ryder, N. S., Wagner, S. & Leitner, I. (1996). In vitro activity of terbinafine against Candida and other yeasts by the NCCLS method. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract E55, p. 91. American Society for Microbiology, Washington, DC.
85. Rodero, L., Vitale, R., Hochenfellner, F., Canteros, C. & Davel, G. (1996). In vitro activity of terbinafine in combination with triazole drugs against fluconazole resistant candida species. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract E56, p. 91. American Society for Microbiology, Washington, DC.
86. Ryder, N. S. & Leitner, I. (1998). Synergistic activity of terbinafine and triazoles against Pseudallescheria boydii clinical isolates in vitro. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J115, p. 484. American Society for Microbiology, Washington, DC.
87. Kirkpatrick, W. R., Mcatee, R. K., Ryder, N. S. & Patterson, T. F. (1998). Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J77, p. 473. American Society for Microbiology, Washington, DC.
88. Pappas, P., Restrepo, A., Dietze, R., Foss, N. T., Bustamante, B., Nolazco, D. et al. (1998). Terbinafine treatment of cutaneous sporotrichosis: initial results from a phase II/III trial. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J96, p. 478. American Society for Microbiology, Washington, DC.
89. Dominguez, J. M. & Martin, J. J. (1998). Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans. Antimicrobial Agents and Chemotherapy 42, 2279-83.
90. Dominguez, J. M., Kelly, V. A., Kinsman, O. S., Marriott, M. S., Gomez De Las Heras, F. & Martin, J. (1998). Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrobial Agents and Chemotherapy 42, 2274-8.
91. Alvarez, M. E., Herreros, E., Sanchez-Sousa, A., Gargallo-Viola, D. & Baquero, F. (1998). In vitro activity of sordarins in combination with other systemic antifungal agents against Candida albicans, Aspergillus spp., and Scedosporium apiospermum. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J12, p. 454. American Society for Microbiology, Washington, DC.
92. Herreros, E., Martinez, C. M., Almela, M. J., Lozano, S., Gomez De Las Heras, F. & Gargallo-Viola, D. (1998). Fungicidal activity of sordarins against Candida albicans determined by time-kill methods. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J13, p. 454. American Society for Microbiology, Washington, DC.
93. Aliouat, E,. M., Aviles, P., Dei-Cas, E., Herreros, E., Dujardin, L. & Gargallo-Viola, D. (1998). In vitro pharmacodynamic parameters of sordarin derivatives in comparison with marketed compounds against rat-derived Pneumocystis carinii. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J15, p. 454. American Society for Microbiology, Washington, DC.
94. Aviles, P., Falcoz, C., Efthymiopoulos, C., San Roman, R., Martinez, A., Jiminez, E. et al. (1998). Pharmacokinetic/pharmacodynamic (PK/PD) study of sordarin derivatives in a lethal C. albicans infection in mice. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J74, p. 472. American Society for Microbiology, Washington, DC.
95. Gatehouse, D. G., Williams, T. C., Sullivan, A. T., Apperley, G. H., Close, S. P., Nesfield, S. R. et al. (1998). Sordarins: toxicological evaluation and safety pharmacology in rats and dogs. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J75, p. 472. American Society for Microbiology, Washington, DC.
96. Capa, L., Mendoza, A., Lavandera, J. L., Gomez De Las Heras, F. & Garcia-Bustos, J. F. (1998). Translation elongation factor 2 is part of the target for a new family of antifungals. Antimicrobial Agents and Chemotherapy 42, 2694-9.
97. Herreros, E., Martinez, C. M., Almela, M. J., Marriott, M. S., Gomez De Las Heras, F. & Gargallo-Viola, D. (1998). Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Antimicrobial Agents and Chemotherapy 42, 2863-9.
98. Zamarro, M. T., Martin, J. J. & Dominguez, J. M. (1998). Sordarins inhibit Aspergillus fumigatus protein synthesis. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J83, p. 474. American Society for Microbiology, Washington, DC.
99. De Luca, A. J., Bland, J. M., Jacks, T. J., Grimm, C. & Walsh, T. J. (1998). Fungicidal and binding properties of the natural peptides cecropin B and Dermaseptin. Medical Mycology 36, 291-8.
100. Hong, S. Y., Oh, J. E., Kwon, M. Y., Choi, M. J., Lee, J. H., Lee, B. L. et al. (1998). Identification and characterization of novel antimicrobial decapeptides generated by combinatorial chemistry. Antimicrobial Agents and Chemotherapy 42, 2534-41.
101. Delucca, A. J., Bland, J. M., Vigo, C., Peter, J. & Walsh, T. J. (1998). Fungicidal and enzymatic resistance properties of a novel synthetic peptide, D-cecropin B. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J-80, p. 474. American Society for Microbiology, Washington, DC.
102. Pettit, R. K., Pettit, G. R. & Hazen, K. C. (1998). Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy 42, 2961-5.
103. Del Poeta, M., Schell, W. A., Dykstra, C. C., Jones, S. J., Tidwell, R. R., Kumar, A. et al. (1998). In vitro antifungal activities of a series of dication-substituted carbazoles, furans, and benzimidazoles. Antimicrobial Agents and Chemotherapy 42, 2503-10.
104. Bartlett, M. S., Edline, T. D., Shaw, M. M. & Wheat, L. J. (1998). Carbendazim cures histoplasmosis in mice. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J58, p. 467. American Society for Microbiology, Washington, DC.
105. Utsunomiya, T., Kobayashi, M., Kobayashi, H., Pollard, R. B. & Suzuki, F. (1998). Antifungal effect of glycyrrhizin (GR) on Candida albicans infection in thermally injured mice. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J66, p. 470. American Society for Microbiology, Washington, DC.
106. Ziegelbauer, K., Babczinski, P. & Schonfeld, W. (1998). Molecular mode of action of the antifungal B-amino acid BAY 10-8888. Antimicrobial Agents and Chemotherapy 42, 2197-205.